Q1 results preview: Here's why pharma companies are expected to show improvement
Nuvama Institutional Equities expects better Q1FY24 results for pharmaceutical companies, with revenue and EBITDA growth predicted to be 16%/30% YoY and 4%/7% QoQ, respectively.